HomeBIOTECHNOLOGYSingle Use Support Providing Solutions For Gene Therapies

Single Use Support Providing Solutions For Gene Therapies

Biopharma solution provider Single Use Support announces an order from Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO).

The Indianapolis-based CDMO has ordered RoSS.FILL CGT to fill lentiviral vectors into small single-use bags. Specially designed for cell and gene therapies, RoSS.FILL CGT is an automated cGMP-compliant filling and filtration platform to dispense small to medium sized volumes of highly valuable drug substances into multiple small single use bags. The technology will be supplied to Genezen’s facility by the end of 2021.

Growing together
The CEOs of the Austrian-based process solution provider Single Use Support, Thomas Wurm and Johannes Kirchmair, are delighted to secure the deal with Genezen. “We are proud to be supporting Genezen with their automated filling manufacturing process and to be part of their ongoing major growth”, said Wurm referring to the current expansion of the CDMO in Indianapolis. “We are both fast-paced companies with a high degree of innovation – it will be a great match”, Kirchmair adds.

Commenting on the announcement, newly appointed Genezen CEO, Ray Kaczmarek added: “It’s an exciting time to announce this agreement with SUSupport as Genezen makes significant strides towards the completion of our new multiphase 75,000+ square foot cGMP lentiviral and retroviral vector production facility in early 2022. Our facility will deliver cGMP-compliant viral vector production and a full suite of complementary process development capabilities to support commercial readiness.”

“Having partners such as SUSupport in place will be one of many essential components as we scale our operations to deliver high-quality programs and vector production services to our clients.”, Kaczmarek adds.

Growing expertise in cell and gene therapies
End-to-end process solutions from Single Use Support have proven to be successful at laboratory but also commercial scale in the production of bulk drug substance. Its involvement in the production of COVID-19 vaccines and mAbs demonstrated that the industry relies on its portfolio ranging from protection of single-use bags, filling & draining, freezing & thawing, cold storage, and shipping. The purchase from Genezen demonstrates once again the technologies’ flexibility and its applicability to different areas in Biopharma. Cell & gene therapies and upstream seed train intensification are such fields where customers can use solutions for different batch sizes and volumes while remaining independent from any single use bag or bottle.

About Single Use Support GmbH – The Company
What began with a vision in a garage quickly developed into a global technology company. Single Use Support GmbH was founded in 2016 by Johannes Kirchmair and Thomas Wurm. The company specializes in the development and production of mechatronic systems for the pharmaceutical industry and develops solutions for a 100% safe liquid logistics process. Single Use Support offers innovative product solutions that enable high-quality, essential medicines to be transported safely, sterile and frozen around the globe in so-called single-use bags. Customers of the innovative Tyrolean company with headquarters in Kufstein are well-known pharmaceutical companies in Europe, Asia and America. Single Use Support has over 100 employees and will exceed an annual turnover of EUR 100 million in 2021. More here.


Other News

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.

Improve Your Cell Viability with INTEGRA Liquid Handling Solutions

This equipment is designed to offer enhanced pipetting speed control, limiting the stress placed on cells during handling to improve cell viability.

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

The Saragene test kits approved by the CDSCO use the Company's patented CoPrimer™ technology for the qualitative detection of these mosquito-borne viruses.

54gene Closes $25M Series B

The round also included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, Ingressive Capital and others.